Sensei Biotherapeutics Inc (SNSE) Stock Price, Quote & News

Company Profile

Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune ch...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 243 8000

Website: www.senseibio.com

Address:

1405 Research Boulevard, Suite 125, Rockville, United States

topstockalerts Aug. 3 at 2:18 PM

Fridays Top Gainers PT2 $FDMT $RAYA $SNSE $LXEH $MGRT

0 · Reply

StockScanners Aug. 2 at 9:12 PM

$SNSE Keep watch if this holds above 9.30

0 · Reply

IntraTrades Aug. 1 at 9:32 PM

$FGF 90.36% $EQ 77.50% $LOBO 60.36% $EZGO 49.21% $SNSE 38.03%

0 · Reply

JFZ Aug. 1 at 9:17 PM

$FDMT $LXEH $MGRT $RAYA $SNSE

0 · Reply

topstockalerts Aug. 1 at 9:04 PM

Todays Top Gainers PT2 $FDMT $RAYA $SNSE $LXEH $MGRT

0 · Reply

Godwins26 Aug. 1 at 8:08 PM

Even during After hours Let's get our money we deserve it all the hard hours of trading $RAYA $EQ $FGF $SNSE $MWYN

0 · Reply

LeftyT Aug. 1 at 7:53 PM

$SNSE I picked this up just before Christmas at $9.00/sh because I liked their tumor micro-environment targeting and release approach. Watched it flop around for 8 months and was pleasantly surprised to see it jump today and put me back in the green. Still trading way below cash value w/ VERY low float and clean balance sheet. Could make a nice move going into their ESMO presentation on October 17. Stay tuned!!!

0 · Reply

topstockalerts Aug. 1 at 7:39 PM

$SNSE keep it on your radar for next week..👀👀

0 · Reply

Godwins26 Aug. 1 at 7:35 PM

$RAYA $EQ $FGF $SNSE $MWYN

0 · Reply

Aburose Aug. 1 at 7:28 PM

$SNSE let’s go to 20-25

0 · Reply

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 30, 2025, 7:30 AM EDT - 8 days ago

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

Jun 13, 2025, 7:30 AM EDT - 7 weeks ago

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

May 6, 2025, 7:30 AM EDT - 3 months ago

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

Apr 2, 2025, 7:30 AM EDT - 4 months ago

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 28, 2025, 7:30 AM EDT - 4 months ago

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

Mar 27, 2025, 4:05 PM EDT - 4 months ago

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

Feb 4, 2025, 7:30 AM EST - 6 months ago

Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 8, 2025, 7:30 AM EST - 7 months ago

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

Nov 27, 2024, 4:05 PM EST - 9 months ago

Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference

Nov 14, 2024, 7:30 AM EST - 9 months ago

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 29, 2024, 7:30 AM EDT - 10 months ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Present at Upcoming Conferences

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

May 30, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

May 23, 2024, 5:10 PM EDT - 1 year ago

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

May 10, 2024, 11:45 AM EDT - 1 year ago

EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member

May 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

Apr 9, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

Apr 4, 2024, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Mar 22, 2024, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Mar 6, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

Feb 28, 2024, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

Nov 7, 2023, 7:30 AM EST - 1 year ago

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Nov 3, 2023, 4:05 PM EDT - 1 year ago

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

Nov 1, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Oct 25, 2023, 9:05 AM EDT - 1 year ago

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

Oct 23, 2023, 7:30 AM EDT - 1 year ago

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

Sep 27, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

Sep 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

Sep 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immuno

Aug 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

Aug 3, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Aug 2, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

Jun 13, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

Jun 1, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

May 9, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

Apr 20, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Apr 18, 2023, 4:05 PM EDT - 2 years ago

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 30, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual Symposium

Mar 28, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights

Mar 21, 2023, 7:30 AM EDT - 2 years ago

Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody

Mar 14, 2023, 4:35 PM EDT - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual Meeting 2023

Mar 7, 2023, 5:15 PM EST - 2 years ago

Sensei Biotherapeutics Adopts Stockholder Rights Agreement

Mar 6, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Participate in Oppenheimer's 33rd Annual Healthcare Conference

Feb 21, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

Feb 16, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Participate in Citi's 2023 Virtual Oncology Leadership Summit

Feb 14, 2023, 7:30 AM EST - 2 years ago

Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics

topstockalerts Aug. 3 at 2:18 PM

Fridays Top Gainers PT2 $FDMT $RAYA $SNSE $LXEH $MGRT

0 · Reply

StockScanners Aug. 2 at 9:12 PM

$SNSE Keep watch if this holds above 9.30

0 · Reply

IntraTrades Aug. 1 at 9:32 PM

$FGF 90.36% $EQ 77.50% $LOBO 60.36% $EZGO 49.21% $SNSE 38.03%

0 · Reply

JFZ Aug. 1 at 9:17 PM

$FDMT $LXEH $MGRT $RAYA $SNSE

0 · Reply

topstockalerts Aug. 1 at 9:04 PM

Todays Top Gainers PT2 $FDMT $RAYA $SNSE $LXEH $MGRT

0 · Reply

Godwins26 Aug. 1 at 8:08 PM

Even during After hours Let's get our money we deserve it all the hard hours of trading $RAYA $EQ $FGF $SNSE $MWYN

0 · Reply

LeftyT Aug. 1 at 7:53 PM

0 · Reply

topstockalerts Aug. 1 at 7:39 PM

$SNSE keep it on your radar for next week..👀👀

0 · Reply

Godwins26 Aug. 1 at 7:35 PM

$RAYA $EQ $FGF $SNSE $MWYN

0 · Reply

Aburose Aug. 1 at 7:28 PM

$SNSE let’s go to 20-25

0 · Reply

Godwins26 Aug. 1 at 7:21 PM

New Watchlist today 😊 $RAYA $EQ $FGF $SNSE $MWYN

0 · Reply

topstockalerts Aug. 1 at 7:08 PM

$SNSE setting up nicely..

0 · Reply

50shadesoftrades Aug. 1 at 6:31 PM

$LOBO Intraday gainers(right) $EQ $FGF $SNSE $MGRT

0 · Reply

topstockalerts Aug. 1 at 6:30 PM

$SNSE can’t say you weren’t warned.. 🔥

0 · Reply

Aburose Aug. 1 at 6:09 PM

$SNSE maybe heading toward 20

0 · Reply

LabPsycho Aug. 1 at 6:07 PM

$SNSE @AllandaleCapital Well, that was a rather prescient and incredibly well timed post yesterday.

1 · Reply

topstockalerts Aug. 1 at 5:57 PM

Top Gainers PT2 $SNSE $VVOS $FDMT $WK $ATEC

1 · Reply

ThatDudeWithNoMoney Aug. 1 at 5:33 PM

$IVF once all news media sites begin reporting on the IVF, Trumps administration will have to acknowledge it and potentially sign the executive order; anything is possible 👀👀👀👀 $TNON $LOBO $SNSE *This is strictly speculative insight and not financial advice*

0 · Reply

LabPsycho Aug. 1 at 5:20 PM

$SNSE bottomed out, plateauing, and likely going up into October as predicted below is my guess.

0 · Reply

S2K_TradeZ Aug. 1 at 4:48 PM

$SNSE wow what a crazy gain here! 6.5 -> 10.0 🚨🔥🦍

0 · Reply

ujouy Aug. 1 at 4:37 PM

$SNSE Doing very good today

0 · Reply

Aburose Aug. 1 at 4:35 PM

$SNSE maybe move today

0 · Reply

Market Cap	10.39M
Revenue (ttm)	0.00
Net Income (ttm)	-30.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	6,521
Avg Vol	16,964
Day's Range	N/A - N/A
Shares Out	1.26M
Stochastic %K	41%
Beta	0.26
Analysts	Strong Sell
Price Target	$35.00